Proteomic analysis of heart failure hospitalization among patients with chronic kidney disease: The Heart and Soul Study

被引:13
|
作者
Dubin, Ruth F. [1 ]
Whooley, Mary [2 ]
Pico, Alexander [3 ]
Genz, Peter [4 ]
Schiller, Nelson B. [5 ]
Meyer, Craig [2 ]
机构
[1] Univ Calif San Francisco, San Francisco VA Med Ctr, Div Nephrol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA USA
[3] Univ Calif San Francisco, Gladstone Inst, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Div Cardiol, Zuckerberg San Francisco Gen Hosp, San Francisco, CA USA
[5] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA
来源
PLOS ONE | 2018年 / 13卷 / 12期
关键词
GLOMERULAR-FILTRATION-RATE; STAGE RENAL-DISEASE; CARDIOVASCULAR-DISEASE; ALL-CAUSE; RISK; MORTALITY; EVENTS; ASSOCIATIONS; ALBUMINURIA; BIOMARKERS;
D O I
10.1371/journal.pone.0208042
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Patients with chronic kidney disease (CKD) are at increased risk for heart failure (HF). We aimed to investigate differences in proteins associated with HF hospitalizations among patients with and without CKD in the Heart and Soul Study. Methods and results We measured 1068 unique plasma proteins from baseline samples of 974 participants in The Heart and Soul Study who were followed for HF hospitalization over a median of 7 years. We sequentially applied forest regression and Cox survival analyses to select prognostic proteins. Among participants with CKD, four proteins were associated with HF at Bonferroni-level significance (p<2.5x10(-4)): Angiopoietin-2 (HR[95%CI] 1.45[1.33, 1.59]), Spondin-1 (HR[95%CI] 1.13[1.06, 1.20]), tartrate-resistant acid phosphatase type 5 (HR[95%CI] 0.65[0.53, 0.78]) and neurogenis locus notch homolog protein 1 (NOTCH1) (HR[95%CI] 0.67[0.55, 0.80]). These associations persisted at p<0.01 after adjustment for age, estimated glomerular filtration and history of HF. CKD was a significant interaction term in the associations of NOTCH1 and Spondin-1 with HF. Pathway analysis showed a trend for higher representation of the Cardiac Hypertrophy and Complement/Coagulation pathways among proteins prognostic of HF in the CKD sub-group. Conclusions These results suggest that markers of heart failure differ between patients with and without CKD. Further research is needed to validate novel markers in cohorts of patients with CKD and adjudicated HF events.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Prevalence of chronic kidney disease in patients with congestive heart failure at heart failure outpatient clinic
    Losic, R.
    Bevc, S. B.
    [J]. EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2015, 14 : S76 - S77
  • [22] OPTIMAL MANAGEMENT OF CHRONIC HEART FAILURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE
    Zachariah, Donah
    Kaira, Philip A.
    Kaira, Paul R.
    [J]. JOURNAL OF RENAL CARE, 2009, 35 (01) : 2 - 10
  • [23] Xanthine metabolism in chronic heart failure patients with chronic kidney disease
    Smolianyk, K. Kateryna
    Bilchenko, A.
    Kolomiiets, M.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 138 - 138
  • [24] CHRONIC KIDNEY DISEASE IN THE EVALUATION OF COMORBIDITY IN PATIENTS WITH CHRONIC HEART FAILURE
    Efremova, E.
    Shutov, A.
    [J]. ATHEROSCLEROSIS, 2020, 315 : E263 - E264
  • [25] Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure
    Mari Katsumata
    Nobuhito Hirawa
    Koichiro Sumida
    Minako Kagimoto
    Yosuke Ehara
    Yuki Okuyama
    Megumi Fujita
    Akira Fujiwara
    Mayumi Kobayashi
    Yusuke Kobayashi
    Yuichiro Yamamoto
    Sanae Saka
    Keisuke Yatsu
    Tetsuya Fujikawa
    Yoshiyuki Toya
    Gen Yasuda
    Kouichi Tamura
    Satoshi Umemura
    [J]. Clinical and Experimental Nephrology, 2017, 21 : 858 - 865
  • [26] Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure
    Katsumata, Mari
    Hirawa, Nobuhito
    Sumida, Koichiro
    Kagimoto, Minako
    Ehara, Yosuke
    Okuyama, Yuki
    Fujita, Megumi
    Fujiwara, Akira
    Kobayashi, Mayumi
    Kobayashi, Yusuke
    Yamamoto, Yuichiro
    Saka, Sanae
    Yatsu, Keisuke
    Fujikawa, Tetsuya
    Toya, Yoshiyuki
    Yasuda, Gen
    Tamura, Kouichi
    Umemura, Satoshi
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2017, 21 (05) : 858 - 865
  • [27] Reversibility of chronic heart failure symptoms in chronic kidney disease patients
    Belov, V. V.
    Ilyicheva, O. E.
    [J]. CARDIOVASCULAR THERAPY AND PREVENTION, 2007, 6 (01): : 68 - 72
  • [28] Heart Failure in Hemodialysis Patients: An Interim Analysis of the DERAIL Study (Development and Regulation of Heart Failure with Preserved Ejection Fraction in Patients with Chronic Kidney Disease)
    Antlanger, M.
    Aschauer, S.
    Kopecky, C.
    Mascherbauer, J.
    Saeemann, M.
    Bonderman, D.
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2014, 126 : S93 - S93
  • [29] Hemodialysis and outcome in patients with heart failure and chronic kidney disease
    Leskovar, B.
    Furlan, T.
    Adamlje, A.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 319 - 320
  • [30] Device Therapy in Heart Failure Patients With Chronic Kidney Disease
    Badheka, Apurva
    Rathod, Ankit
    Tuliani, Tushar
    Afonso, Luis
    Jacob, Sony
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (05) : 542 - 543